July 16, 2026 - 23:38

Pentair has turned to a familiar face to steady its financial leadership. Bob Fishman, who stepped down as the company's chief financial officer just five months ago, is returning to the role on an interim basis. The move comes as the water treatment and filtration company navigates a period of transition in its executive ranks.
Fishman originally resigned from the top finance seat in March of this year. His departure was announced without a detailed public explanation, though the company noted at the time that it was beginning a search for a permanent replacement. That search is still ongoing, and Pentair has now decided to bring Fishman back to fill the gap in the short term.
The decision to recall a former CFO is not uncommon in corporate America, especially when a company wants to maintain stability while it continues looking for a long-term hire. Fishman is already familiar with Pentair's operations, financial strategies, and reporting structures, which should allow him to step in without a steep learning curve.
Pentair has not provided a timeline for when it expects to name a permanent CFO. In the meantime, Fishman will oversee the company's financial planning, accounting, and investor relations. The company's stock has shown modest movement since the announcement, with analysts noting that the interim appointment removes some near-term uncertainty.
Fishman's return signals that Pentair values continuity and experience over rushing a permanent hire. For now, the company's finance team will be led by a leader who already knows the numbers and the culture.
August 31, 2026 - 00:01
Honda (HMC), Nissan Edge Toward a Software AllianceHonda Motor Co. Ltd. and Nissan Motor are reportedly nearing a deal to work together on vehicle software and onboard computer systems. According to Japan`s Nikkei newspaper, an agreement could be...
August 30, 2026 - 12:20
Laureate Education (LAUR) Looks Fairly Valued, Is There Enough Upside Left?Laureate Education (LAUR) has caught the eye of investors after the stock closed at US$38.80 on 26 August 2026. The recent trading pattern shows a slight cooling over the last day, but the broader...
August 29, 2026 - 22:05
AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?Investors looking at large-cap pharma in 2026 face a clear fork in the road. Eli Lilly has ridden the wave of metabolic drugs like Mounjaro and Zepbound to a stunning 45 percent revenue jump,...
August 29, 2026 - 04:14
BillionToOne's Co-Founder Sells 10,000 Shares for $1 MillionA significant insider transaction has been recorded at molecular diagnostics firm BillionToOne, with one of its co-founders selling a substantial block of company stock. The sale involved 10,000...